Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects with Chronic Immune (Idiopathic) Thrombocytopenic Purpura

    Summary
    EudraCT number
    2007-003569-42
    Trial protocol
    ES  
    Global end of trial date
    03 Mar 2009

    Results information
    Results version number
    v1(current)
    This version publication date
    20 Jun 2016
    First version publication date
    06 Aug 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    20060195
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00515203
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Amgen, Inc
    Sponsor organisation address
    One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
    Public contact
    IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
    Scientific contact
    IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Mar 2009
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Mar 2009
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.
    Protection of trial subjects
    This study was conducted in accordance with appropriate country regulations and the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Essential documents will be retained in accordance with ICH GCP. Before any subject participated in the study, the investigator was to obtain written informed consent from the subject or legally acceptable representative following adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. Informed consent was to be obtained before any protocol-specific screening procedures or administration of investigational product. In addition to written informed consent, the assent of the child from those subjects capable of providing assent must have been obtained if requested by the IRB/IEC. Copies of the protocol, informed consent form, and other written subject information were submitted to the IEC or IRB for written approval. A copy of the written approval of the protocol and informed consent form was received by Amgen before recruitment of subjects into the study and shipment of investigational product.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    19 Jul 2007
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 2
    Country: Number of subjects enrolled
    United States: 18
    Country: Number of subjects enrolled
    Australia: 2
    Worldwide total number of subjects
    22
    EEA total number of subjects
    2
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    2
    Children (2-11 years)
    12
    Adolescents (12-17 years)
    8
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants were enrolled from 19 Jul 2007 through 11 November 2008

    Pre-assignment
    Screening details
    Subjects were boys and girls aged 12 months to < 18 years with ITP diagnosed at least 6 months prior to screening and severe thrombocytopenia (mean of 2 screening platelet counts ≤ 30 x 10^9/L with no single count > 35 x 10^9/L). Concurrent corticosteroid therapy was allowed.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Placebo by subcutaneous injection once weekly
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Administered by subcutaneous injection

    Arm title
    Romiplostim
    Arm description
    Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg.
    Arm type
    Experimental

    Investigational medicinal product name
    Romiplostim
    Investigational medicinal product code
    AMG 531
    Other name
    Nplate
    Pharmaceutical forms
    Powder for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Administered by subcutaneous injection

    Number of subjects in period 1
    Placebo Romiplostim
    Started
    5
    17
    Completed
    5
    17

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Romiplostim
    Reporting group description
    Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg.

    Reporting group title
    Placebo
    Reporting group description
    Placebo by subcutaneous injection once weekly

    Reporting group values
    Romiplostim Placebo Total
    Number of subjects
    17 5 22
    Age categorical
    Units: Subjects
        12 months to < 3 years
    3 1 4
        3 years to < 12 years
    8 2 10
        12 years to < 18 years
    6 2 8
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    9.4 ( 5.4 ) 9.8 ( 4.6 ) -
    Gender, Male/Female
    Units: Participants
        Female
    4 2 6
        Male
    13 3 16
    Race, Customized
    Units: Subjects
        White or Caucasian
    9 4 13
        Black or African American
    5 0 5
        Hispanic or Latino
    3 0 3
        Other
    0 1 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo by subcutaneous injection once weekly

    Reporting group title
    Romiplostim
    Reporting group description
    Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg.

    Primary: Adverse Events

    Close Top of page
    End point title
    Adverse Events [1]
    End point description
    Occurrence of one or more adverse events in the participant during the 12-week treatment period.
    End point type
    Primary
    End point timeframe
    12 weeks
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The nature of analyses for this endpoint was descriptive and no formal hypothesis testing was performed.
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Participants
        number (not applicable)
    16
    5
    No statistical analyses for this end point

    Secondary: Weeks with Platelet Count ≥ 50 x 10^9/L

    Close Top of page
    End point title
    Weeks with Platelet Count ≥ 50 x 10^9/L
    End point description
    The number of weeks with platelet count ≥ 50 x 10^9/L during the 12 week treatment period.
    End point type
    Secondary
    End point timeframe
    12-week treatment period
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Weeks
        arithmetic mean (standard deviation)
    5.65 ( 3 )
    0 ( 0 )
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Romiplostim v Placebo
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0019
    Method
    Cochran-Mantel-Haenszel
    Confidence interval

    Secondary: Bleeding Events (Grade 2 or higher)

    Close Top of page
    End point title
    Bleeding Events (Grade 2 or higher)
    End point description
    Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)
    End point type
    Secondary
    End point timeframe
    12-week treatment period (Weeks 2 - 13)
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Events per participant
        arithmetic mean (standard deviation)
    0.41 ( 1 )
    0 ( 0 )
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Romiplostim v Placebo
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3651
    Method
    Cochran-Mantel-Haenszel
    Confidence interval

    Secondary: Platelet count ≥ 50 x 10^9/L for two consecutive weeks

    Close Top of page
    End point title
    Platelet count ≥ 50 x 10^9/L for two consecutive weeks
    End point description
    Participant incidence of achieving a platelet count ≥50 x 10^9/L for two consecutive weeks during the 12 week treatment period.
    End point type
    Secondary
    End point timeframe
    12-week treatment period
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Participants
        number (not applicable)
    15
    0
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Romiplostim v Placebo
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0008
    Method
    Fisher exact
    Confidence interval

    Secondary: Increase in platelet count ≥ 20 x 10^9/L above baseline for two consecutive weeks

    Close Top of page
    End point title
    Increase in platelet count ≥ 20 x 10^9/L above baseline for two consecutive weeks
    End point description
    Participant incidence of achieving an increase in platelet count ≥20 x 10^9/L above baseline for two consecutive weeks during the 12 week treatment period.
    End point type
    Secondary
    End point timeframe
    12-week treatment period
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Participants
        number (not applicable)
    15
    0
    Statistical analysis title
    Statisticla Analysis
    Comparison groups
    Romiplostim v Placebo
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0008
    Method
    Fisher exact
    Confidence interval

    Secondary: Requirement for Rescue Therapy (as defined per protocol)

    Close Top of page
    End point title
    Requirement for Rescue Therapy (as defined per protocol)
    End point description
    Participant required rescue therapy (as defined per protocol) during the 12 week treatment period.
    End point type
    Secondary
    End point timeframe
    12-week treatment period
    End point values
    Romiplostim Placebo
    Number of subjects analysed
    17
    5
    Units: Participants
        number (not applicable)
    2
    2
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Romiplostim v Placebo
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.2098
    Method
    Fisher exact
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    16 weeks
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.1
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Placebo by subcutaneous injection once weekly

    Reporting group title
    Romiplostim
    Reporting group description
    Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg

    Serious adverse events
    Placebo Romiplostim
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 5 (0.00%)
    2 / 17 (11.76%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Blood and lymphatic system disorders
    Lymphadenitis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Influenza
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo Romiplostim
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    5 / 5 (100.00%)
    16 / 17 (94.12%)
    Vascular disorders
    Haematoma
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Haemorrhage
         subjects affected / exposed
    0 / 5 (0.00%)
    2 / 17 (11.76%)
         occurrences all number
    0
    2
    General disorders and administration site conditions
    Chest discomfort
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Injection site haematoma
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Injection site haemorrhage
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Malaise
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Pain
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Pyrexia
         subjects affected / exposed
    0 / 5 (0.00%)
    5 / 17 (29.41%)
         occurrences all number
    0
    6
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Reproductive system and breast disorders
    Genital haemorrhage
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Menorrhagia
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Vaginal discharge
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Cough
         subjects affected / exposed
    2 / 5 (40.00%)
    2 / 17 (11.76%)
         occurrences all number
    3
    2
    Dyspnoea exertional
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Epistaxis
         subjects affected / exposed
    1 / 5 (20.00%)
    6 / 17 (35.29%)
         occurrences all number
    1
    8
    Nasal congestion
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 17 (0.00%)
         occurrences all number
    2
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 5 (0.00%)
    4 / 17 (23.53%)
         occurrences all number
    0
    4
    Pharyngeal erythema
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Respiratory tract congestion
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Wheezing
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Emotional disorder
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Investigations
    Spleen palpable
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    1 / 5 (20.00%)
    3 / 17 (17.65%)
         occurrences all number
    3
    4
    Fall
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Scratch
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Skin laceration
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 17 (5.88%)
         occurrences all number
    1
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Headache
         subjects affected / exposed
    2 / 5 (40.00%)
    6 / 17 (35.29%)
         occurrences all number
    2
    11
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 17 (5.88%)
         occurrences all number
    2
    1
    Abdominal pain upper
         subjects affected / exposed
    0 / 5 (0.00%)
    3 / 17 (17.65%)
         occurrences all number
    0
    4
    Chapped lips
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Diarrhoea
         subjects affected / exposed
    0 / 5 (0.00%)
    2 / 17 (11.76%)
         occurrences all number
    0
    2
    Mouth haemorrhage
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Toothache
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    2 / 5 (40.00%)
    2 / 17 (11.76%)
         occurrences all number
    2
    2
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Hyperhidrosis
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Petechiae
         subjects affected / exposed
    1 / 5 (20.00%)
    2 / 17 (11.76%)
         occurrences all number
    2
    3
    Pruritus
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    4
    Rash
         subjects affected / exposed
    0 / 5 (0.00%)
    3 / 17 (17.65%)
         occurrences all number
    0
    5
    Rash macular
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    3
    Skin nodule
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Urethral disorder
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Back pain
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 17 (5.88%)
         occurrences all number
    1
    1
    Inguinal mass
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Pain in extremity
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 17 (5.88%)
         occurrences all number
    1
    1
    Infections and infestations
    Ear infection
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Herpes simplex
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 17 (0.00%)
         occurrences all number
    1
    0
    Infection
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    0 / 5 (0.00%)
    2 / 17 (11.76%)
         occurrences all number
    0
    2
    Otitis media
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Otitis media acute
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Sinusitis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 5 (20.00%)
    2 / 17 (11.76%)
         occurrences all number
    2
    3
    Urinary tract infection
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 17 (5.88%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Aug 2007
    Major Changes: • Replaced the use of the romiplostim diluent with a commercially available diluent.
    04 Sep 2008
    Major Changes: • Updated consent form to provide updated patient exposure numbers and percentage of subjects who have reported adverse events.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 10:41:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA